<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00614380</url>
  </required_header>
  <id_info>
    <org_study_id>1235.7</org_study_id>
    <secondary_id>EUDRACT2007-002410-19</secondary_id>
    <nct_id>NCT00614380</nct_id>
  </id_info>
  <brief_title>Open Label Study Telmisartan and Amlodipine in Hypertension</brief_title>
  <official_title>An Open Label Follow-up Trial of the Efficacy and Safety of Chronic Administration of the Combination of Telmisartan 40mg + Amlodipine 5mg or the Combination of Telmisartan 80mg + Amlodipine 5mg Tablets Alone or in Combination With Other Antihypertensive Medications in Patients With Hypertension.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of this trial is to assess the efficacy and safety of the fixed dose
      combinations telmisartan 40 mg / amlodipine 5 mg (T40/A5) or telmisartan 80 mg / amlodipine 5
      mg (T80/A5) during long-term open-label treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Trough Seated Diastolic Blood Pressure (DBP) Control</measure>
    <time_frame>End of study (34 weeks or last value on treatment)</time_frame>
    <description>The number of patients who reach the target DBP of &lt;90mmHg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trough Seated Systolic Blood Pressure (SBP) Control</measure>
    <time_frame>End of study (34 weeks or last value on treatment)</time_frame>
    <description>The number of patients who reach the target SBP of &lt;140mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Trough Seated Diastolic Blood Pressure</measure>
    <time_frame>End of study (34 weeks or last value on treatment)</time_frame>
    <description>Change from baseline to the end of study in trough DBP. Baseline is defined as visit 3 of trial 1235.5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in DBP From Last Available Trough in 1235.5 to Last Available Trough in 1235.7</measure>
    <time_frame>End of study (34 weeks or last value on treatment)</time_frame>
    <description>The difference between the last available troughs represents the additional reduction in DBP in this study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Trough Seated Systolic Blood Pressure</measure>
    <time_frame>End of study (34 weeks or last value on treatment)</time_frame>
    <description>Change from baseline to the end of study in trough SBP. Baseline is defined as visit 3 of trial 1235.5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SBP From Last Available Trough in 1235.5 to Last Available Trough in 1235.7</measure>
    <time_frame>End of study (34 weeks or last value on treatment)</time_frame>
    <description>The difference between the last available troughs represents the additional reduction in SBP in this study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Seated DBP Response</measure>
    <time_frame>End of study (34 weeks or last value on treatment)</time_frame>
    <description>The number of patients who reach the target DBP of &lt;90mmHg or had a reduction in DBP &gt;= 10mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Seated SBP Response</measure>
    <time_frame>End of study (34 weeks or last value on treatment)</time_frame>
    <description>The number of patients who reach the target SBP of &lt;140mmHg or had a reduction in SBP &gt;= 15 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Blood Pressure (BP) Normality Classes</measure>
    <time_frame>End of study (34 weeks or last value on treatment)</time_frame>
    <description>The number of patients who reach predefined BP categories</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Additional Antihypertensive</measure>
    <time_frame>At any point during open-label treatment</time_frame>
    <description>Time from first intake of medication to first intake of an antihypertensive other than the study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Requiring Additional Antihypertensive Therapy to Achieve DBP Control</measure>
    <time_frame>At any point during open-label treatment</time_frame>
    <description>The number of patients with DBP control (DBP&lt;90 mmHg). Last trough DBP measurement before taking additional antihypertensive compared to last trough DBP taken on treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional Reduction in DBP by Use of Additional Antihypertensive Therapy</measure>
    <time_frame>At any point during open-label treatment</time_frame>
    <description>Difference in trough DBP from last visit before add-on therapy and last visit during 1235.7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional Reduction in SBP by Use of Additional Antihypertensive Therapy</measure>
    <time_frame>At any point during open-label treatment</time_frame>
    <description>Difference in trough SBP from last visit before add-on therapy and last visit during 1235.7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough DBP Control Pre- and Post- Uptitration</measure>
    <time_frame>At any point during open-label treatment</time_frame>
    <description>The number of patients with DBP control (DBP&lt;90 mmHg). Last trough DBP measurement before uptitration to Telmisartan 80mg compared to first trough DBP taken after uptitration</description>
  </secondary_outcome>
  <enrollment type="Actual">976</enrollment>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>telmisartan/amlodipine 40/5 mg fixed combination</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>telmisartan/amlodipine 80/5 mg fixed combination</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. patients aged at least 18 years

          2. diagnosis of essential hypertension and blood pressure not adequately controlled
             before enrolment in the preceding trial.

          3. failure to respond to six weeks treatment with Amlodipine 5 mg in the run-in period of
             the preceding trial.

        Exclusion Criteria:

          1. pre-menopausal women who are not surgically sterile; or are nursing or pregnant; or
             are not practising acceptable means of birth control or do not plan to continue using
             acceptable means of birth control throughout the study

          2. development of any medical condition in the preceding trial that in the investigator's
             opinion could be worsened by treatment with either Telmisartan 40 mg/Amlodipine 5 mg
             or Telmisartan 80 mg/Amlodipine 5 mg

          3. discontinuation from the preceding trial because of any adverse event or any other
             reason

          4. known or suspected secondary hypertension

          5. mean seated Systolic Blood Pressure =&gt; 180 mmHg and/or mean seated Diastolic Blood
             Pressure =&gt; 120 mmHg at any visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1235.7.32004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aywaille</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.32010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gozée</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.32008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Linkebeek</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.32003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mol</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.32007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Natoye</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.32002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tienen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.32005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Turnhout</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.20001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Coquitlam</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.20011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.20007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bay Roberts</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.20005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mount Pearl</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.20008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.20013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Corunna</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.20014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Etobicoke</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.20010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.20012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.20009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.20006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.20003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.45002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Birkerød</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.45005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Haderslev</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.45008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Herning</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.45009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hinnerup</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.45001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rødovre</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.45006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rødovre</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.45003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vaerløse</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.45007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vildbjerg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.35003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joensuu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.35004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joensuu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.35001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.35002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.3301H Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aigrefeuille S/Maine</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.3306C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.3309B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.3309C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.3309E Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.3309D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Avrille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.3309A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beaucouze</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.3305A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bourg des cptes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.3306D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Briollay</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.3308B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cholet</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.3308F Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cholet</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.3302C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Garchizy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.3303C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Grandchamps</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.3302D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guerigny</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.3310A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jarny</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.3301L Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Chapelle /s Erdre</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.3301J Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Chapelle sur Erdre</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.3304A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Fresnais</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.3308E Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Jubaudière</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.3301G Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Montagne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.3307D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Le Mesnil en Vallée</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.3301E Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Le Temple de Bretagne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.3309F Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Les Ponts de CE</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.3305B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Louvigné le Bais</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.3307E Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mouliherne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.3306A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Murs Erigne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.3307A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Murs-Erigne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.3301A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.3301B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.3301D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.3301M Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.3302A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nevers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.3302F Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nevers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.3301I Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nort sur Erdre</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.3301C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Orvault</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.3307F Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Parcay les Pins</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.3301N Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sautron</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.3306B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Segre</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.3301F Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St Aubin les Châteaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.3306F Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St Georges de Montaigu</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.3304B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St Ouen La Rouerie</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.3306E Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Thouars</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.3304C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tinténiac</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.3308A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vihiers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.82007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.82001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.82006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Daejon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.82004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gangwon-Do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.82008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.82002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.82003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.82005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.31008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beerzerveld</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.31006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bennebroek</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.31004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hoogwoud</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.31003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Musselkanaal</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.31007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nijverdal</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.31001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oude Pekela</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.31005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roelofarendsveen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.31010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Voerendaal</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.47002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.47003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamar</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.47004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.47001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ålesund</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.63006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Makati City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.63001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.63002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.63009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.63008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pasay City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.63005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pasig City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.63003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.63007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.27003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boksburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.27006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.27009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.27010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.27004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.27007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.27008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.27001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Krugersdorp</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.27005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lenasia</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.27002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.46002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.46003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.46005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Luleå</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.46004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rättvik</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.46001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.88605 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Changhua</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.88608 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hualien City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.88601 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.7.88603 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Philippines</country>
    <country>South Africa</country>
    <country>Sweden</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2008</study_first_submitted>
  <study_first_submitted_qc>February 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2008</study_first_posted>
  <results_first_submitted>December 14, 2009</results_first_submitted>
  <results_first_submitted_qc>December 14, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 18, 2010</results_first_posted>
  <last_update_submitted>December 16, 2013</last_update_submitted>
  <last_update_submitted_qc>December 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Telmisartan 40mg and Amlodipine 5mg</title>
        </group>
        <group group_id="P2">
          <title>Telmisartan 80mg and Amlodipine 5mg</title>
        </group>
        <group group_id="P3">
          <title>Telmisartan 40mg and Amlodipine 5mg + add-on Antihypertensive</title>
        </group>
        <group group_id="P4">
          <title>Telmisartan 80mg and Amlodipine 5mg + add-on Antihypertensive</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="564"/>
                <participants group_id="P2" count="206"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="181"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="529"/>
                <participants group_id="P2" count="198"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="179"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non compliant with the protocol</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Consent withdrawn</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Telmisartan 40mg and Amlodipine 5mg</title>
        </group>
        <group group_id="B2">
          <title>Telmisartan 80mg and Amlodipine 5mg</title>
        </group>
        <group group_id="B3">
          <title>Telmisartan 40mg and Amlodipine 5mg + add-on Antihypertensive</title>
        </group>
        <group group_id="B4">
          <title>Telmisartan 80mg and Amlodipine 5mg + add-on Antihypertensive</title>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="564"/>
            <count group_id="B2" value="206"/>
            <count group_id="B3" value="25"/>
            <count group_id="B4" value="181"/>
            <count group_id="B5" value="976"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.8" spread="10.9"/>
                    <measurement group_id="B2" value="52.9" spread="10.6"/>
                    <measurement group_id="B3" value="54.4" spread="10.8"/>
                    <measurement group_id="B4" value="52.4" spread="9.6"/>
                    <measurement group_id="B5" value="53.9" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="240"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="45"/>
                    <measurement group_id="B5" value="365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="324"/>
                    <measurement group_id="B2" value="134"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="136"/>
                    <measurement group_id="B5" value="611"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Trough Seated Diastolic Blood Pressure (DBP) Control</title>
        <description>The number of patients who reach the target DBP of &lt;90mmHg</description>
        <time_frame>End of study (34 weeks or last value on treatment)</time_frame>
        <population>The full analysis set of patients. All patients who took at least one dose of study medication and have at least one on treatment BP measurement 20-30 hours post dose</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40mg and Amlodipine 5mg</title>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80mg and Amlodipine 5mg</title>
          </group>
          <group group_id="O3">
            <title>Telmisartan 40mg and Amlodipine 5mg + add-on Antihypertensive</title>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80mg and Amlodipine 5mg + add-on Antihypertensive</title>
          </group>
        </group_list>
        <measure>
          <title>Trough Seated Diastolic Blood Pressure (DBP) Control</title>
          <description>The number of patients who reach the target DBP of &lt;90mmHg</description>
          <population>The full analysis set of patients. All patients who took at least one dose of study medication and have at least one on treatment BP measurement 20-30 hours post dose</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="553"/>
                <count group_id="O2" value="206"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes (DBP&lt;90 mmHg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="504"/>
                    <measurement group_id="O2" value="160"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No (DBP&gt;=90 mmHg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.22</ci_lower_limit>
            <ci_upper_limit>0.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.12</ci_lower_limit>
            <ci_upper_limit>0.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.06</ci_lower_limit>
            <ci_upper_limit>0.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.34</ci_lower_limit>
            <ci_upper_limit>2.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.16</ci_lower_limit>
            <ci_upper_limit>0.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.10</ci_lower_limit>
            <ci_upper_limit>0.72</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Seated Systolic Blood Pressure (SBP) Control</title>
        <description>The number of patients who reach the target SBP of &lt;140mmHg</description>
        <time_frame>End of study (34 weeks or last value on treatment)</time_frame>
        <population>The full analysis set of patients. All patients who took at least one dose of study medication and have at least one on treatment BP measurement 20-30 hours post dose</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40mg and Amlodipine 5mg</title>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80mg and Amlodipine 5mg</title>
          </group>
          <group group_id="O3">
            <title>Telmisartan 40mg and Amlodipine 5mg + add-on Antihypertensive</title>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80mg and Amlodipine 5mg + add-on Antihypertensive</title>
          </group>
        </group_list>
        <measure>
          <title>Trough Seated Systolic Blood Pressure (SBP) Control</title>
          <description>The number of patients who reach the target SBP of &lt;140mmHg</description>
          <population>The full analysis set of patients. All patients who took at least one dose of study medication and have at least one on treatment BP measurement 20-30 hours post dose</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="553"/>
                <count group_id="O2" value="206"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes (SBP&lt;140 mmHg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="440"/>
                    <measurement group_id="O2" value="142"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No (SBP&gt;=140 mmHg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Trough Seated Diastolic Blood Pressure</title>
        <description>Change from baseline to the end of study in trough DBP. Baseline is defined as visit 3 of trial 1235.5.</description>
        <time_frame>End of study (34 weeks or last value on treatment)</time_frame>
        <population>All patients who took at least one dose of study medication, have a trough baseline measurement (Visit 3 1235.5) and at least one on treatment BP measurement 20-30 hours post dose</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40mg and Amlodipine 5mg</title>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80mg and Amlodipine 5mg</title>
          </group>
          <group group_id="O3">
            <title>Telmisartan 40mg and Amlodipine 5mg + add-on Antihypertensive</title>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80mg and Amlodipine 5mg + add-on Antihypertensive</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough Seated Diastolic Blood Pressure</title>
          <description>Change from baseline to the end of study in trough DBP. Baseline is defined as visit 3 of trial 1235.5.</description>
          <population>All patients who took at least one dose of study medication, have a trough baseline measurement (Visit 3 1235.5) and at least one on treatment BP measurement 20-30 hours post dose</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="549"/>
                <count group_id="O2" value="203"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.18" spread="0.31"/>
                    <measurement group_id="O2" value="-12.64" spread="0.52"/>
                    <measurement group_id="O3" value="-9.47" spread="1.51"/>
                    <measurement group_id="O4" value="-10.17" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in DBP From Last Available Trough in 1235.5 to Last Available Trough in 1235.7</title>
        <description>The difference between the last available troughs represents the additional reduction in DBP in this study</description>
        <time_frame>End of study (34 weeks or last value on treatment)</time_frame>
        <population>Full Analysis Set (FAS) included patients who took at least one dose of study medication and have at least one on treatment BP measurement</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40mg and Amlodipine 5mg</title>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80mg and Amlodipine 5mg</title>
          </group>
          <group group_id="O3">
            <title>Telmisartan 40mg and Amlodipine 5mg + add-on Antihypertensive</title>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80mg and Amlodipine 5mg + add-on Antihypertensive</title>
          </group>
        </group_list>
        <measure>
          <title>Change in DBP From Last Available Trough in 1235.5 to Last Available Trough in 1235.7</title>
          <description>The difference between the last available troughs represents the additional reduction in DBP in this study</description>
          <population>Full Analysis Set (FAS) included patients who took at least one dose of study medication and have at least one on treatment BP measurement</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="545"/>
                <count group_id="O2" value="203"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.54" spread="0.33"/>
                    <measurement group_id="O2" value="-5.52" spread="0.55"/>
                    <measurement group_id="O3" value="-5.51" spread="1.59"/>
                    <measurement group_id="O4" value="-5.74" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Trough Seated Systolic Blood Pressure</title>
        <description>Change from baseline to the end of study in trough SBP. Baseline is defined as visit 3 of trial 1235.5.</description>
        <time_frame>End of study (34 weeks or last value on treatment)</time_frame>
        <population>Full Analysis Set (FAS) included patients who took at least one dose of study medication and have at least one on treatment BP measurement</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40mg and Amlodipine 5mg</title>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80mg and Amlodipine 5mg</title>
          </group>
          <group group_id="O3">
            <title>Telmisartan 40mg and Amlodipine 5mg + add-on Antihypertensive</title>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80mg and Amlodipine 5mg + add-on Antihypertensive</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough Seated Systolic Blood Pressure</title>
          <description>Change from baseline to the end of study in trough SBP. Baseline is defined as visit 3 of trial 1235.5.</description>
          <population>Full Analysis Set (FAS) included patients who took at least one dose of study medication and have at least one on treatment BP measurement</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="549"/>
                <count group_id="O2" value="203"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.79" spread="0.52"/>
                    <measurement group_id="O2" value="-15.91" spread="0.86"/>
                    <measurement group_id="O3" value="-12.6" spread="2.5"/>
                    <measurement group_id="O4" value="-14.04" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in SBP From Last Available Trough in 1235.5 to Last Available Trough in 1235.7</title>
        <description>The difference between the last available troughs represents the additional reduction in SBP in this study</description>
        <time_frame>End of study (34 weeks or last value on treatment)</time_frame>
        <population>All patients who took at least one dose of study medication, have a trough baseline measurement (Last value on treatment in 1235.5) and at least one on treatment BP measurement 20-30 hours post dose</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40mg and Amlodipine 5mg</title>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80mg and Amlodipine 5mg</title>
          </group>
          <group group_id="O3">
            <title>Telmisartan 40mg and Amlodipine 5mg + add-on Antihypertensive</title>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80mg and Amlodipine 5mg + add-on Antihypertensive</title>
          </group>
        </group_list>
        <measure>
          <title>Change in SBP From Last Available Trough in 1235.5 to Last Available Trough in 1235.7</title>
          <description>The difference between the last available troughs represents the additional reduction in SBP in this study</description>
          <population>All patients who took at least one dose of study medication, have a trough baseline measurement (Last value on treatment in 1235.5) and at least one on treatment BP measurement 20-30 hours post dose</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="545"/>
                <count group_id="O2" value="203"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.14" spread="0.5"/>
                    <measurement group_id="O2" value="-5.62" spread="0.83"/>
                    <measurement group_id="O3" value="-3.6" spread="2.41"/>
                    <measurement group_id="O4" value="-7.17" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Seated DBP Response</title>
        <description>The number of patients who reach the target DBP of &lt;90mmHg or had a reduction in DBP &gt;= 10mmHg</description>
        <time_frame>End of study (34 weeks or last value on treatment)</time_frame>
        <population>The full analysis set of patients. All patients who took at least one dose of study medication and have at least one on treatment BP measurement 20-30 hours post dose</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40mg and Amlodipine 5mg</title>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80mg and Amlodipine 5mg</title>
          </group>
          <group group_id="O3">
            <title>Telmisartan 40mg and Amlodipine 5mg + add-on Antihypertensive</title>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80mg and Amlodipine 5mg + add-on Antihypertensive</title>
          </group>
        </group_list>
        <measure>
          <title>Trough Seated DBP Response</title>
          <description>The number of patients who reach the target DBP of &lt;90mmHg or had a reduction in DBP &gt;= 10mmHg</description>
          <population>The full analysis set of patients. All patients who took at least one dose of study medication and have at least one on treatment BP measurement 20-30 hours post dose</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="553"/>
                <count group_id="O2" value="206"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes (Responder)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="504"/>
                    <measurement group_id="O2" value="171"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No (Non-responder)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Seated SBP Response</title>
        <description>The number of patients who reach the target SBP of &lt;140mmHg or had a reduction in SBP &gt;= 15 mmHg</description>
        <time_frame>End of study (34 weeks or last value on treatment)</time_frame>
        <population>The full analysis set of patients. All patients who took at least one dose of study medication and have at least one on treatment BP measurement 20-30 hours post dose</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40mg and Amlodipine 5mg</title>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80mg and Amlodipine 5mg</title>
          </group>
          <group group_id="O3">
            <title>Telmisartan 40mg and Amlodipine 5mg + add-on Antihypertensive</title>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80mg and Amlodipine 5mg + add-on Antihypertensive</title>
          </group>
        </group_list>
        <measure>
          <title>Trough Seated SBP Response</title>
          <description>The number of patients who reach the target SBP of &lt;140mmHg or had a reduction in SBP &gt;= 15 mmHg</description>
          <population>The full analysis set of patients. All patients who took at least one dose of study medication and have at least one on treatment BP measurement 20-30 hours post dose</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="553"/>
                <count group_id="O2" value="206"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes (Responder)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="490"/>
                    <measurement group_id="O2" value="179"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No (Non-responder)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Blood Pressure (BP) Normality Classes</title>
        <description>The number of patients who reach predefined BP categories</description>
        <time_frame>End of study (34 weeks or last value on treatment)</time_frame>
        <population>The full analysis set of patients. All patients who took at least one dose of study medication and have at least one on treatment BP measurement 20-30 hours post dose</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40mg and Amlodipine 5mg</title>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80mg and Amlodipine 5mg</title>
          </group>
          <group group_id="O3">
            <title>Telmisartan 40mg and Amlodipine 5mg + add-on Antihypertensive</title>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80mg and Amlodipine 5mg + add-on Antihypertensive</title>
          </group>
        </group_list>
        <measure>
          <title>Trough Blood Pressure (BP) Normality Classes</title>
          <description>The number of patients who reach predefined BP categories</description>
          <population>The full analysis set of patients. All patients who took at least one dose of study medication and have at least one on treatment BP measurement 20-30 hours post dose</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="553"/>
                <count group_id="O2" value="206"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Optimal (SBP&lt;120 and DBP&lt;80 mmHg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal (SBP&lt;130 and DBP&lt;85 mmHg and not optimal)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High-normal (SBP&lt;140 DBP&lt;90 mmHg and not normal)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163"/>
                    <measurement group_id="O2" value="92"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage 1 hypertension (SBP&lt;160 and DBP&lt;100 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122"/>
                    <measurement group_id="O2" value="73"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage 2 hypertension (SBP&gt;=160 and DBP&gt;=100 mmHg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Additional Antihypertensive</title>
        <description>Time from first intake of medication to first intake of an antihypertensive other than the study drug</description>
        <time_frame>At any point during open-label treatment</time_frame>
        <population>Patients from the full analysis set who took additional antihypertensive medication as defined by the investigator. Full analysis set defined as all patients who took at least one dose of study medication and have at least one on treatment BP measurement 20-30 hours post dose</population>
        <group_list>
          <group group_id="O1">
            <title>Total</title>
          </group>
        </group_list>
        <measure>
          <title>Time to First Additional Antihypertensive</title>
          <description>Time from first intake of medication to first intake of an antihypertensive other than the study drug</description>
          <population>Patients from the full analysis set who took additional antihypertensive medication as defined by the investigator. Full analysis set defined as all patients who took at least one dose of study medication and have at least one on treatment BP measurement 20-30 hours post dose</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.8" spread="38.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Requiring Additional Antihypertensive Therapy to Achieve DBP Control</title>
        <description>The number of patients with DBP control (DBP&lt;90 mmHg). Last trough DBP measurement before taking additional antihypertensive compared to last trough DBP taken on treatment</description>
        <time_frame>At any point during open-label treatment</time_frame>
        <population>Patients from the full analysis set who took additional antihypertensive medication as defined by the investigator. Full analysis set defined as all patients who took at least one dose of study medication and have at least one on treatment BP measurement 20-30 hours post dose</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-antihypertensive: Yes (DBP&lt;90 mmHg)</title>
          </group>
          <group group_id="O2">
            <title>Pre-antihypertensive: No (DBP&gt;=90 mmHg)</title>
          </group>
          <group group_id="O3">
            <title>Pre-antihypertensive: Total</title>
          </group>
        </group_list>
        <measure>
          <title>Patients Requiring Additional Antihypertensive Therapy to Achieve DBP Control</title>
          <description>The number of patients with DBP control (DBP&lt;90 mmHg). Last trough DBP measurement before taking additional antihypertensive compared to last trough DBP taken on treatment</description>
          <population>Patients from the full analysis set who took additional antihypertensive medication as defined by the investigator. Full analysis set defined as all patients who took at least one dose of study medication and have at least one on treatment BP measurement 20-30 hours post dose</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="206"/>
                <count group_id="O3" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post-antihypertensive: Yes (DBP&lt;90 mmHg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-antihypertensive: No (DBP&gt;=90 mmHg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="106"/>
                    <measurement group_id="O3" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-antihypertensive: Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="206"/>
                    <measurement group_id="O3" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Additional Reduction in DBP by Use of Additional Antihypertensive Therapy</title>
        <description>Difference in trough DBP from last visit before add-on therapy and last visit during 1235.7</description>
        <time_frame>At any point during open-label treatment</time_frame>
        <population>Patients from the full analysis set who took additional antihypertensive medication as defined by the investigator. Full analysis set defined as all patients who took at least one dose of study medication and have at least one on treatment BP measurement 20-30 hours post dose</population>
        <group_list>
          <group group_id="O1">
            <title>Total</title>
          </group>
        </group_list>
        <measure>
          <title>Additional Reduction in DBP by Use of Additional Antihypertensive Therapy</title>
          <description>Difference in trough DBP from last visit before add-on therapy and last visit during 1235.7</description>
          <population>Patients from the full analysis set who took additional antihypertensive medication as defined by the investigator. Full analysis set defined as all patients who took at least one dose of study medication and have at least one on treatment BP measurement 20-30 hours post dose</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.73" spread="7.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Additional Reduction in SBP by Use of Additional Antihypertensive Therapy</title>
        <description>Difference in trough SBP from last visit before add-on therapy and last visit during 1235.7</description>
        <time_frame>At any point during open-label treatment</time_frame>
        <population>Patients from the full analysis set who took additional antihypertensive medication as defined by the investigator. Full analysis set defined as all patients who took at least one dose of study medication and have at least one on treatment BP measurement 20-30 hours post dose</population>
        <group_list>
          <group group_id="O1">
            <title>Total</title>
          </group>
        </group_list>
        <measure>
          <title>Additional Reduction in SBP by Use of Additional Antihypertensive Therapy</title>
          <description>Difference in trough SBP from last visit before add-on therapy and last visit during 1235.7</description>
          <population>Patients from the full analysis set who took additional antihypertensive medication as defined by the investigator. Full analysis set defined as all patients who took at least one dose of study medication and have at least one on treatment BP measurement 20-30 hours post dose</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.53" spread="11.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough DBP Control Pre- and Post- Uptitration</title>
        <description>The number of patients with DBP control (DBP&lt;90 mmHg). Last trough DBP measurement before uptitration to Telmisartan 80mg compared to first trough DBP taken after uptitration</description>
        <time_frame>At any point during open-label treatment</time_frame>
        <population>Patients from the full analysis set who up-titrated to the higher dose of telmisartan 80 mg and amlodipine 10 mg. Full analysis set defined as all patients who took at least one dose of study medication and have at least one on treatment BP measurement 20-30 hours post dose</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-titration: Yes (DBP&lt;90 mmHg)</title>
          </group>
          <group group_id="O2">
            <title>Pre-titration: No (DBP&gt;=90 mmHg)</title>
          </group>
          <group group_id="O3">
            <title>Pre-titration: Total</title>
          </group>
        </group_list>
        <measure>
          <title>Trough DBP Control Pre- and Post- Uptitration</title>
          <description>The number of patients with DBP control (DBP&lt;90 mmHg). Last trough DBP measurement before uptitration to Telmisartan 80mg compared to first trough DBP taken after uptitration</description>
          <population>Patients from the full analysis set who up-titrated to the higher dose of telmisartan 80 mg and amlodipine 10 mg. Full analysis set defined as all patients who took at least one dose of study medication and have at least one on treatment BP measurement 20-30 hours post dose</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="361"/>
                <count group_id="O3" value="378"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post-titration: Yes (DBP&lt;90 mmHg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="190"/>
                    <measurement group_id="O3" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-titration: No (DBP&gt;=90 mmHg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="171"/>
                    <measurement group_id="O3" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-titration: Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="361"/>
                    <measurement group_id="O3" value="378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From day of first dose until one day after last dose</time_frame>
      <desc>Safety analysis treatment groups were based upon actual treatment received at the time of the event regardless of add-on antihypertensive. All patients started the study on Telmisartan 40mg and amlodipine 5mg and were up-titrated according to DBP response. Explaining the large number of patients exposed to T40/A5 compared to T80/A5</desc>
      <group_list>
        <group group_id="E1">
          <title>Telmisartan 40mg and Amlodipine 5mg</title>
        </group>
        <group group_id="E2">
          <title>Telmisartan 80mg and Amlodipine 5mg</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="976"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="976"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="976"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="976"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Cronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="976"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="976"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Cystic lymphangioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="976"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="976"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="976"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="976"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Post procedural cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="976"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Typhoid fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="976"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="976"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="976"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="976"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="976"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="976"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="976"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Muscular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="976"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="976"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="976"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="976"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="976"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Hypotonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="976"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="976"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="976"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Urinary bladder polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="976"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="976"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="976"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="976"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="976"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Perpheral artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="976"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="976"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="976"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="976"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

